HALO

91.3501.82%
HI

Helen I. Torley

President, CEO & Director

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prior to joining Halozyme in January 2014, she served as the Chief Commercial Officer and Executive Vice President of Onyx Pharmaceuticals, Inc. since August 29, 2011 until December 2013, where she oversaw the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. Dr. Torley served as Vice President and General Manager of Nephrology Business Unit at Amgen Inc. since October 2003 to 2011. She joined Amgen Inc. in June 2002 as Therapeutic Area Head of Inflammation Global Marketing. She serves as the Chief Commercial Officer and Executive Vice President at Onyx Pharmaceuticals Internatiaonal GmbH. Dr. Torley served as Chief Operating Officer of Onyx Pharmaceuticals, Inc. She had been an Independent Director of Quest Diagnostics Incorporated since May 17, 2018 until May 18, 2022. She began her industry career at Sandoz/Novartis in 1990, heading up the clinical development program for Sand immune in rheumatoid arthritis. During her 7 years at Novartis, she held positions of increasing responsibility in medical marketing and marketing, ultimately serving as Vice President of Medical Affairs, with responsibility for medical marketing and phase IIIB/IV trials across all therapeutic areas. In 1997, Dr. Torley joined Bristol-Myers Squibb and held various positions, including Regional Vice President of cardiovascular and metabolic sales, heading up the 150 sales representatives from the California sales team. She was Senior Registrar in rheumatology at the Royal Infirmary, Glasgow, Scotland. Dr. Torley has board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches. She has been a Director of Vifor Pharma, Inc. (formerly known as Relypsa, Inc.). since January 2015 and Halozyme Therapeutics, Inc. since January 6, 2014. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B) from University of Glasgow in 1984 and her MRCP from the Royal College of Physicians, Glasgow, Scotland in 1987.

Positions